How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

694 results for

Dysuria in Children

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Pemphigus

Diseases (E- Rare) grant 113301091 from the Netherlands Organisation for Health Research and Development (ZON-MW); Stichting Vlinderkind (Dutch Butterfly Child) Foundation; DEBRA International 2 Consulting fee or honorarium No No Abbott B.V. 3 Support for travel to meetings for the study or other purposes No No No 4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like No No No 5 Payment for writing or reviewing (...) ? Nurse specialist/practitioner 7 2.3 CLINICAL EXAMINATION 2.3.1 Medical History ? It should specify the time of first onset of symptoms. ? It should specify functional symptoms, i.e. pain, pruritus, intensity of dysphagia, ocular and ENT symptoms, dysuria, anogenital problems and weight loss. ? It should include a haematological, oncologic, endocrine, cardiovascular and infectious medical history to search for risk factors of oral corticosteroid treatment and evolving complications

2013 European Dermatology Forum

222. Guideline for consultations requiring sexual history taking

should have their competency to consent to history taking, examination and treatment assessed and this assessment should be documented in the clinical notes.[67,68] IV, C. Safeguarding children Where there are any concerns regarding a child’s safety, there should always be serious consideration given to liaison with the local safeguarding children team. [69,70] Answers to the following additional questions may flag up the need for further assessment and liaison with the local safeguarding children (...) team: Whether parents/carers are aware of the child’s sexual activity Whether parents/carers are aware of the child’s attendance at the clinic Whether the child has ever had non-consensual sexual contact Age of sexual partner(s) Vulnerability (e.g. self-harm, psychiatric illness, drug or alcohol misuse, where there is an imbalance of power, eg youth workers/teachers, or grooming is likely) Where children under the age of 13 years report sexual activity, this should be discussed with a senior

2013 British Association for Sexual Health and HIV

223. Adjuvant and Salvage Radiation Therapy After Prostatectomy Guideline

frequency was rare (0.4%). Grade 1 and 2 dysuria occurred in 37.9% and 10.3% of patients, respectively, with only 1.1% reporting grade 3 dysuria and no reports of grade 4. Hematuria was uncommon, with 3.7% of patients exhibiting grade 1, 0.9% exhibiting grade 2 and no patients exhibiting the higher grades. With regard to acute GI effects, Goenka 99 reported that 3D-CRT patients had higher levels of grade 2 or greater toxicities (13.2%) compared to IMRT patients (7.6%). Alongi 174 divided toxicities

2013 American Society for Radiation Oncology

224. Catheterisation Urethral Intermittent in adults

in adults and not for children. Furthermore, these guidelines are intended to complement, or provide support to, established clinical practice and should be used within the context of local policies and existing protocols and with recognition of the individual situation of the patient. This text is made available to all individual EAUN members, both electronically and in print. The full text can be accessed on the EAU website (http://www.uroweb.org/nurses/nursing- guidelines/) and the EAUN website (...) . Such patients may be incontinent. [3] • P o s t - v oid r e s idu al (P VR) Post-void residual (PVR) is defined as the volume of urine left in the bladder at the end of micturition. [3] • B act er iur i a For a urine specimen collected by in and out catheter, a count of > 100 CFU/ml is consistent with bacteriuria [8] Symptomatic bacteriuria is a significant number of microorganisms in the urine that occurs together with urinary tract symptoms such as dysuria and fever Asymptomatic bacteriuria is defined

2013 European Association of Urology Nurses

225. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society

lactobacillus species. Un- fortunately, the newer diagnostic tests for BV often use Avaginaeasoneofthemarkersofvaginaldisease.Thismay lead to unnecessary antibiotic treatment of postmenopausal women and the potential disturbance of their very fragile microbiome. 24 PRESENTATION OF SYMPTOMATIC VULVOVAGINAL ATROPHY Commonly reported symptoms include dryness, irritation of vulva, burning, dysuria, dyspareunia, and vaginal dis- charge. 2,6,31,32 Symptoms of VVA can be severe enough to interfere with a woman_s (...) become obliterated, making the cervix flush with the vault. Petechiae may be seen in the vestibule or vagina. With atrophic vaginitis, brown or yellow secretions may be present. With severe VVA, there may be such shortening of the vaginal vault and narrowing of the introitus that spec- uluminsertionandvisualinspectionofthevaginalvaultmay not be possible. Small pediatric speculums with lubrication may be helpful with severe atrophy. Although assessment of the vaginal maturation index (VMI) and vaginal

2013 The North American Menopause Society

226. Macroscopic haematuria - a urological approach

Melissa Yeoh Nai Kid Lai Daniel Anderson Vinesh Appadurai Haematuria is defined as evidence of blood in the urine under microscopy. It is a common symptom of both benign and malignant conditions. This article will discuss the differential diagnosis of haematuria from a urological perspective, important investigations to determine the cause, and resultant management. there is a range of conditions that can cause both macroscopic and microscopic haematuria. in Australia, microscopic haematuria (...) in Table 1. Risk factors for haematuria Risk factors can help in determining which patients are at higher risk of urinary tract and bladder cancer. Risk factors include: 2,6 • age >40 years • a history of smoking • history of gross haematuria • history of chronic cystitis or irritative lower urinary tract symptoms (eg. frequency, urgency, dysuria, nocturia, hesitancy, sensation of incomplete emptying) • pelvic irradiation Macroscopic haematuria – a urological approach clinical 124 Reprinted from

2013 Clinical Practice Guidelines Portal

227. Catheterisation Indwelling catheters in adults ? Urethral and Suprapubic

as competent in this procedure. Although these guidelines aim to be comprehensive, effective practice can only be achieved if the nurse or practitioner has a clear and thorough knowledge of the anatomy under discussion and the necessary grasp and understanding of basic nursing principles. This publication focuses on indwelling catheters both suprapubic and urethral. The guidelines only describe the procedure and material in adults and not for children. Furthermore, these guidelines are intended (...) be recommended routinely Unresolved Issue 5.2.2 Catheter diameter size and length Catheter diameter sizes are measured in Charrière (Ch or CH) also know as French Gauge (F , Fr or FG) and indicate the external diameter. 1 mm = 3 Ch and the sizes range from Ch 6 to 30. For paediatric use: size 6-10 For adults: size 10 Clear urine, no debris, no grit (encrustation) size 12-14 Clear urine, no debris, no grit, no haematuria size 16 Slightly cloudy urine, light haematuria with or without small clots, none or mild

2012 European Association of Urology Nurses

228. Adult Urodynamics: AUA/SUFU Guideline

is present. ( Option ; Evidence Quality: Grade C ) 19. Clinicians may perform videourodynamics in properly selected patients to localize the level of obstruction, particularly for the diagnosis of primary bladder neck obstruction. (Expert Opinion) Purpose Lower urinary tract symptoms (LUTS), which include urinary incontinence, are a common and significant source of impaired quality of life and comorbidity in large numbers of adults and children. Commonly, patients presenting with LUTS have overlapping (...) /mixed incontinence or pelvic organ prolapse. Studies published after March 10, 2011 were not included as part of the evidence base considered by the Panel from which evidence-based guideline statements (Standards, Recommendations, Options) were derived. Data from studies published after the literature search cut-off will be incorporated into the next version of this guideline. Preclinical studies (e.g., animal models), pediatric studies, meeting abstracts, commentary, editorials, non-English

2012 American Urological Association

229. Adult Urodynamics: AUA/SUFU Guideline

and significant source of impaired quality of life and comorbidity in large numbers of adults and children. Commonly, patients presenting with LUTS have overlapping symptoms and conditions, making an isolated or homogeneous source of symptoms rare. Clinicians evaluating these disorders collectively utilize history, physical examination, questionnaires and pad testing data in the evaluation of symptoms. Urodynamics (UDS) is the dynamic study of the transport, storage and evacuation of urine. UDS (...) will be incorporated into the next version of this guideline. Preclinical studies (e.g., animal models), pediatric studies, meeting abstracts, commentary, editorials, non -English language studies and studies of adults with urological conditions and symptoms other than those Purpose and Methodology Copyright © 2012 American Urological Association Education and Research, Inc.® 4 AUA/SUFU Guideline Adult Urodynamics noted above were excluded. Studies with less than 10 patients were excluded from further evaluation

2012 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction

230. Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

was assigned one primary and one secondary author. In addi- tion, a pediatric expert provided input to sections that were relevant to children’s health care. A ? nal meeting was con- vened with the committee members to review and approve the recommendations. 1.2 Con? ict of Interest From the outset, each member completed a con? ict of interest (COI) form to be kept on ? le with ACCP. In addition, panel members updated COI forms at the face- to-face meeting and verbally related any changes in con- ? ict (...) : 10.1378/chest.12-1044 Downloaded From: http://journal.publications.chestnet.org/ by David Kinnison on 11/09/2012journal.publications.chestnet.org CHEST / 142 / 5 / NOVEMBER 2012 e3S in addition to normal intake in adults; additional volume given to children needs to be calculated on the basis of body weight) on the days of therapy is recommended (Grade 1C) . 3.5e. For patients who undergo or have under- gone cyclophosphamide therapy and develop hematuria, further evaluation is recommended (Grade 1B

2012 American College of Chest Physicians

231. Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder

to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 35 Years to 70 Years (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: CIC/PBS- patients with urinary tract pain or discomfort and dysuria that is present for > 6 months and is not due to acute urinary tract (...) infection, stones or other urinary pathology. rUTI- patients with greater that 2 urinary tract infections in 6 months or greater than 3 urinary tract infections in one year. A UTI is defined as - symptomatic complaints of dysuria, increased frequency of urination, and hesitancy to urinate and a clean catch urinary culture with >103 colony counts of bacteria per milliliter. Exclusion Criteria: Inability to provide written informed consent Inability or unwillingness to adhere to 40 HBOT treatment sessions

2017 Clinical Trials

232. Platelet-Rich Plasma (PRP) Injection in Treatment of Interstitial Cystitis

treatment day if possible. Adverse events including UTI, AUR, large PVR (>150ml), dysuria and micturition pain will be recorded Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 30 participants Intervention Model: Single Group Assignment Intervention Model Description: Intravesicai injection of platelet-rich plasma Masking: None (Open Label) Primary Purpose: Treatment Official Title: Intravesical Injections of Platelet-Rich Plasma (...) diagnosis of acute urinary tract infection Patients have laboratory abnormalities at screening including: ALT> 3 x upper limit of normal range, AST> 3 x upper limit of normal range; Patients have abnormal serum creatinine level > 2 x upper limit of normal range Patients with any contraindication to be urethral catheterization during treatment Female patients who is pregnant, lactating, or with child-bearing potential without contraception. Patients with any other serious disease considered

2017 Clinical Trials

233. YCFM (Youth Correctional Facilities Males)

(NIAID) Study Details Study Description Go to Brief Summary: The proposed study is a single center (with multiple long-term YCFs) treatment trial of the CDC-recommended azithromycin regimen (1 gm PO once) for chlamydia in males. This study is designed primarily to determine the frequency of chlamydia treatment failure following azithromycin in males who do versus do not have urethral symptoms of urethral discharge and/or dysuria. Anticipated enrollment is 446 males, between the age of 12 to 21 years (...) -recommended azithromycin regimen (1 gm PO once) for chlamydia in males residing in long-term gender-segregated YCFs. This study is designed primarily to determine the frequency of chlamydia treatment failure following azithromycin in males who do versus do not have urethral symptoms of urethral discharge and/or dysuria. Males age 12 to 21 years in good health (based on vital signs and provider's clinical evaluation documented in medical records) who are residing in long-term gender-segregated (not co-ed

2017 Clinical Trials

234. The RELIEFâ„¢ Ureteral Stent

obstruction or as a scaffold to promote healing after endoscopic or open/ laparoscopic surgeries involving the ureter. However, there are many morbidities associated with stent placement either due to bladder irritation or backflow of urine to the kidney. The most commonly reported symptoms include urgency, urinary frequency, dysuria, incontinence, hematuria, suprapubic discomfort, and fever due to urinary tract infections and flank pain, which can occur in up to 80% of stented patients. Sometimes (...) : There is no plan to make individual participant data (IPD) available to other researchers Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: Yes Device Product Not Approved or Cleared by U.S. FDA: Yes Pediatric Postmarket Surveillance of a Device Product: No Product Manufactured in and Exported from the U.S.: No Keywords provided by Irina Jaeger, University Hospitals Cleveland Medical Center: ureteral stent Additional relevant MeSH

2017 Clinical Trials

235. Studying the Impact of Exercise on Hot Flashes

and children will not be included. Have current history of fever, cough, dysuria or diarrhea (i.e., signs of infection). Have >10% of hot flashes predictably related to certain food ingestion alcohol intake. Have a history of "easily blushing" and have >10% hot flashes associated with embarrassing events or migraines. Have an MI, stroke, functional decline within 1 month. Have a history of somatoform disorder. Have an estimated creatinine clearance < 60ml/min. Fail to record data in the diary for >3 days

2017 Clinical Trials

236. Multicenter Prospective Trial on Hemorrhoids

is defined as prolapsing internal hemorrhoids at physical examination performed by a colorectal surgeon. Secondary Outcome Measures : Postoperative complications [ Time Frame: 30 days ] The secondary outcomes include postoperative complications (i.e. urinary retention, constipation, dysuria, pruritis ani, anal pain, anal stenosis, unhealed wound, fissure, fecal urgency, incontinence- flatus, incontinence- stool) Eligibility Criteria Go to Information from the National Library of Medicine Choosing (...) Posted: August 10, 2017 Last Update Posted: August 10, 2017 Last Verified: August 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Plan Description: IPD will not be available to other researchers. Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: Yes Device Product Not Approved or Cleared by U.S. FDA: No Pediatric Postmarket Surveillance of a Device Product: No Product Manufactured

2017 Clinical Trials

237. Catheter Management After Pelvic Reconstructive Surgery

the same 16F transurethral catheter placed with a plastic plug and instructed to unplug and drain the catheter when they feel the urge to void, or at least every four hours throughout the day. Subjects in both groups will be provided a large bag for gravity-based drainage during the night. Subjects also will be encouraged to call the research team with any catheter-related questions or concerns including symptoms of urinary tract infection (UTI). Subjects with symptoms of UTI (e.g., dysuria, urgency (...) Device Product: Yes Device Product Not Approved or Cleared by U.S. FDA: No Pediatric Postmarket Surveillance of a Device Product: No Product Manufactured in and Exported from the U.S.: No Keywords provided by Sarah Boyd, Hartford Hospital: pelvic organ prolapse urinary catheters Additional relevant MeSH terms: Layout table for MeSH terms Prolapse Pelvic Organ Prolapse Urinary Retention Pathological Conditions, Anatomical Urination Disorders Urologic Diseases

2017 Clinical Trials

238. RCT of Laser Therapy for GSM

scale [ Time Frame: 1 year ] Dysuria- 10cm visual analogue scale [ Time Frame: 1 year ] Frequency- 10cm visual analogue scale, [ Time Frame: 1 year ] Urgency-10cm visual analogue scale [ Time Frame: 1 year ] Urinary incontinence- 10cm visual analogue scale [ Time Frame: 1 year ] Overall sexual satisfaction- Female sexual function index [ Time Frame: 1 year ] Frequency- 3 day voiding diary [ Time Frame: 1 year ] Urgency- 3 day voiding diary, [ Time Frame: 1 year ] Urinary incontinence- 3 day voiding (...) using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: Female Gender Based Eligibility: Yes Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Dryness and dyspareunia with moderate to severe intensity Vaginal Health Index <15 Absence of menstruation for at least 12 months Recent Negative Pap-smear test (For women over 65 years old a negative pap smear test up

2017 Clinical Trials

239. Efficacy of Antihistamine Dosing-up and add-on Treatment With H2-receptor Antagonist

: 4 weeks ] Sleepiness, dryness, dysuria Number of urticaria control by K-UCT [ Time Frame: 4 weeks ] Before and after treatment Number of urticaria symptom by UAS [ Time Frame: 4 weeks ] Urticaria activity score Quality of life of chronic urticaria by CU-QoL [ Time Frame: 4 weeks ] Quality of life questionnaire for patients with chronic urticaria Number of Patient-controlled urticaria by VAS [ Time Frame: 4 weeks ] evaluation of Patient-controlled urticaria Number of patients using emergency (...) decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 12 Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Chronic urticaria in Ajou

2017 Clinical Trials

240. GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

. Condition or disease Intervention/treatment Phase Genitourinary Abnormality Breast Cancer Female Vaginal Abnormality Urinary Tract Infections Dyspareunia Dysuria Combination Product: Replens and coconut oil Early Phase 1 Detailed Description: Postmenopausal breast cancer survivors who report at least one GSM sign or symptom will be offered participation in an observational, prospective open label trial. Study duration will be 6 months. Evidence of GSM symptoms will be evaluated by a board certified (...) deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: Female Gender Based Eligibility: Yes Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Female Postmenopausal women (defined as last menstrual period > 1 year ago or 6 months ago with FSH >40) who have been

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>